A Phase I/II Study of Lapatinib (Tykerb) Plus Liposomal Doxorubicin Hydrochloride ( Lipo-Dox) for Patients With ErbB2 Positive Metastatic Breast Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Feb 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 16 Aug 2012 New trial record